Answer
Osimertinib mesylate (Tagrisso) has a terminal half-life of approximately 44 hours, based on population pharmacokinetic analysis.
Sources for this answer
- Tagrisso 40 mg film-coated tabletsAstraZeneca UK Limited · emc · SmPC §5.2 Pharmacokinetic properties · Version 33Document updated
Sources checked